A possible role of intracellular calcium in the development of anti-cancer therapy -resistance in lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 853s Year: 2006
The role of Pgp, MRP and LRP expression in chemotherapy response of small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004
Relationship between a clinical drug resistance and immunohistochemical expression of P-glycoprotien, multidrug resistance protein, and p53 in small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 231s Year: 2002
Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010
The selection of candidate microRNA biomarkers of acquired drug resistance in the lung adenocarcinoma cells treated with EGFR TKI Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD Year: 2019
Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients? Source: Eur Respir J 2015; 46: 1548-1550 Year: 2015
MiR-34a favours macrophage polarization switch from M2 to M1 phenotype in non small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002
A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations Source: Annual Congress 2006 - Lung cancer treatment Year: 2006
Overexpression of inhibitor of DNA-binding proteins and angiogenic markers have higher impact on survival of non small cell lung cancer patients Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012
HIF-1α modulation by topoisomerase inhibitors in A549, a non-small cell lung cancer cell line Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007
Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
The human endogenous antibiotic LL-37 promotes growth of lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 153s Year: 2006
CDCA promotes non-small-cell lung cancer (NSCLC) migration by regulating Akt/Erk1/2 signaling pathways Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology Year: 2019
Inhibition of insulin-like growth factor type I (IGF-I) gene in A549 human lung cancer cell line enhances cell apoptosis and causes phenotype changes relevant to increased tumor susceptibility to immune system Source: Eur Respir J 2007; 30: Suppl. 51, 715s Year: 2007
ABCG2 is determinant to SN-38 resistance in non-small cell lung cancer Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005
A case of pulmonary tuberculosis development after receiving immune check point inhibitor in an advanced non-small cell lung cancer Source: International Congress 2019 – Lung cancer? Year: 2019
Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018 Year: 2019
Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019
Functional expressions of EGFP/LKB1 and its kinase domain induced apoptosis and enhanced chemosensitivity in lung cancer cell lines Source: Eur Respir J 2004; 24: Suppl. 48, 5s Year: 2004